Metamfazone

A selective EP4 receptor antagonist (Ki = 0.7 nM versus a Ki &gt 1 &microM for other EP receptors) that has been shown to inhibit inflammation without gastrointestinal toxicity in various animal models for arthritis.

A selective EP4 receptor antagonist (Ki = 0.7 nM versus a Ki &gt 1 &microM for other EP receptors) that has been shown to inhibit inflammation without gastrointestinal toxicity in various animal models for arthritis.

General description The protein encoded by this gene is a death domain containing adaptor molecule that interacts with TNFRSF1A/TNFR1 and mediates programmed cell death signaling and NF-kappaB activation. This protein binds adaptor protein TRAF2,

NGS Multiplex Oligos for MGI (Index primer mix Set I).

NGS Multiplex Oligos for MGI (Index primer mix Set II).

NGS Multiplex Oligos for MGI (Index primer mix Set III).

A selective, irreversible inhibitor of FAAH (IC₅₀ = 7.2 nM) 0.1 mg/kg reduces inflammatory pain in a rat model.

A selective, irreversible inhibitor of FAAH (IC₅₀ = 7.2 nM) 0.1 mg/kg reduces inflammatory pain in a rat model.

PrEST Antigen RASSF3 Ras association (RalGDS/AF-6) domain fa

Remtolumab (anti-IL-17A&amp:TNF-alpha) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab (anti-IL-17A&amp:TNF-alpha) shows dual inhibition of TNFα and IL-17A.

Remtolumab (anti-IL-17A&amp:TNF-alpha) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab (anti-IL-17A&amp:TNF-alpha) shows dual inhibition of TNFα and IL-17A.

Remtolumab (anti-IL-17A&amp:TNF-alpha) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab (anti-IL-17A&amp:TNF-alpha) shows dual inhibition of TNFα and IL-17A.